May 10 (Reuters) - Sierra Oncology Inc SRRA.O :
* SIERRA ONCOLOGY REPORTS FIRST QUARTER RESULTS
* SIERRA ONCOLOGY INC QTRLY LOSS PER SHARE $0.19
* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT
* SIERRA ONCOLOGY INC - SRA737 LOW-DOSE GEMCITABINE COMBINATION PHASE 1/2 TRIAL ADVANCED INTO COHORT EXPANSION PHASE
* SIERRA ONCOLOGY INC - CASH AND CASH EQUIVALENTS TOTALED $133.8 MILLION AS OF MARCH 31, 2018
* SIERRA ONCOLOGY INC - $133.8 MILLION CASH EXPECTED TO FUND PROGRAMS THROUGH APPROXIMATELY MID-2020